<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941118</url>
  </required_header>
  <id_info>
    <org_study_id>MustafaKUPMR-MPS</org_study_id>
    <nct_id>NCT04941118</nct_id>
  </id_info>
  <brief_title>Myofascial Pain Syndrome and Dextrose Prolotherapy</brief_title>
  <official_title>Evaluation of the Effect of Dextrose Prolotherapy on Pain and Function in Women With Myofascial Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mustafa Kemal University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mustafa Kemal University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myofascial pain syndrome is characterized by the presence of hypersensitive points called&#xD;
      trigger points that cause pain, tenderness, spasm, stiffness, limitation of movement,&#xD;
      weakness, taut band within the muscle, and pain reflected by pressing in a muscle group or a&#xD;
      single muscle.&#xD;
&#xD;
      Prolotherapy is a regenerative treatment method in the treatment of chronic musculoskeletal&#xD;
      pain, in which an irritating solution is injected, often hypertonic dextrose, into painful&#xD;
      ligament and tendon attachments and adjacent joint spaces.&#xD;
&#xD;
      In this study, it was aimed to examine the effect of prolotherapy application on pain, neck&#xD;
      range of motion and neck disability in women with myofascial pain syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>First month post-treatment</time_frame>
    <description>0-10 cm visual scale (0: no pain, 10: most severe pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neck Disability Index</measure>
    <time_frame>First month post-treatment</time_frame>
    <description>It measures the functional state of the neck by scoring between 0-5 points according to the severity of pain, consisting of 20 questions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neck joint range of motion measurement</measure>
    <time_frame>First month post-treatment</time_frame>
    <description>Active neck range of motion, which shows the movement of the neck in all directions, is evaluated by goniometric measurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Through study completion, an average of 6 month.</time_frame>
    <description>Edema, ecchymosis, hematoma, allergic reaction, exacerbation of pain, systemic or distant side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Efficacy of Dextrose Prolotherapy in Myofascial Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Only saline and local anesthetic (lidocaine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextrose prolotherapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dextrose, saline and local anesthetic (lidocaine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection of dextrose, local anesthetic and saline to the myofascial trigger point</intervention_name>
    <description>An injection of 5 ml of 5% dextrose prolotherapy using 2.5 ml 10% dextrose, 1 ml 2% local anesthetic (lidocaine), 1.5 ml 0.9% saline will be administered to the active group from at least 10 trigger points.</description>
    <arm_group_label>Dextrose prolotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Local anesthetic and saline injection to the myofascial trigger point</intervention_name>
    <description>A total of 5 ml of solution created by using 4 ml of 0.9% saline and 1 ml of 2% local anesthetic (lidocaine) will be administered to the control group, with at least 10 trigger points.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  60 women aged 20-50 years with a diagnosis of myofascial pain syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cervical radiculopathy, cervical degeneration, neck surgery or trauma in the last&#xD;
             year, injection history for myofascial pain syndrome in the last 6 months, cognitive&#xD;
             impairment and fibromyalgia, rheumatoid arthritis, hypothyroidism, diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Halil Ogut, M.D.</last_name>
    <phone>+90 326 229 1000</phone>
    <phone_ext>5067</phone_ext>
    <email>oguthalil@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hatay Mustafa Kemal University, Tayfur Ata SÃ¶kmen Faculty of Medicine</name>
      <address>
        <city>Hatay</city>
        <zip>31060</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halil Ogut, M.D.</last_name>
      <phone>+90 326 229 1000</phone>
      <phone_ext>5067</phone_ext>
      <email>oguthalil@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Farpour HR, Fereydooni F. Comparative effectiveness of intra-articular prolotherapy versus peri-articular prolotherapy on pain reduction and improving function in patients with knee osteoarthritis: A randomized clinical trial. Electron Physician. 2017 Nov 25;9(11):5663-5669. doi: 10.19082/5663. eCollection 2017 Nov.</citation>
    <PMID>29403602</PMID>
  </reference>
  <reference>
    <citation>Rabago D, Patterson JJ, Mundt M, Kijowski R, Grettie J, Segal NA, Zgierska A. Dextrose prolotherapy for knee osteoarthritis: a randomized controlled trial. Ann Fam Med. 2013 May-Jun;11(3):229-37. doi: 10.1370/afm.1504. Erratum in: Ann Fam Med. 2013 Sep-Oct;11(5):480.</citation>
    <PMID>23690322</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mustafa Kemal University</investigator_affiliation>
    <investigator_full_name>Halil Ogut</investigator_full_name>
    <investigator_title>Assistant Professor Doctor</investigator_title>
  </responsible_party>
  <keyword>Myofascial pain, dextrose prolotherapy, neck disability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

